Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis
Conditions
Perennial Allergic Rhinitis, PAR
Trial Timeline
Oct 1, 2011 โ Dec 1, 2012
NCT ID
NCT01451541About Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01451541. Target conditions include Perennial Allergic Rhinitis, PAR.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01458275 | Phase 3 | Completed |
| NCT01451541 | Phase 3 | Completed |
Competing Products
20 competing products in Perennial Allergic Rhinitis